CD70 binding molecules and methods of use thereof
AssigneeKite Pharma, Inc.
InventorsRuben Alvarez Rodriguez, Armen Mardiros
Life of this patent
Estimating the term…
Abstract
The disclosure provides anti-CD70 antibodies, antigen binding fragments thereof, chimeric antigen receptors (CARs) and engineered T cell receptors (TCRs) comprising an antigen binding molecule that specifically binds to CD70, polynucleotides encoding the same, and in vitro cells comprising the same. The polynucleotides, polypeptides, and in vitro cells described herein can be used in an engineered TCR and/or CAR T cell therapy for the treatment of a patient suffering from a cancer. In one embodiment, the polynucleotides, polypeptides, and in vitro cells described herein can be used for the treatment of multiple myeloma.
Claims17
An isolated polynucleotide encoding a chimeric antigen receptor (CAR) or T cell receptor (TCR) comprising an antigen binding molecule that specifically binds to CD70, wherein the antigen binding molecule comprises the amino acid sequence of SEQ ID NO:
- 44.
A polynucleotide encoding a CAR or TCR, wherein the polynucleotide comprises the nucleic acid sequence of SEQ ID NOs:
- 43.
A CAR or TCR, wherein the CAR or TCR comprises the amino acid sequence of SEQ ID NO:
- 44, wherein the leader sequence of SEQ ID NO:
- 44 is absent.
Dependencies are inferred from the claim text.